Oral glucagon-like peptide conjugates for metabolic diseases
US8759290B2 · kind B2 · utility
15Cited by
0References
7Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Oct 18, 2006 |
| Grant date | Jun 24, 2014 |
| Priority date | — |
| Expiry date | May 2, 2030 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the field of metabolic compound conjugates, methods of forming said conjugates and uses of these conjugates in the treatment of diabetes and conditions related to this condition. The metabolic compound conjugates of this invention include a metabolic peptide having a glucagon-like peptide (GLP-1) receptor binding motif for action on a GLP-1 receptor and at least one oligomer conjugation site for binding with at least one oligomer, wherein the oligomer includes a polyethylene glycol moiety (PEG), and/or alkyl moiety.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.